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Aims Switching between oral anticoagulants and treatment discontinuation are common events related to therapy with non-
vitamin K antagonist oral anticoagulants (NOACs). However, knowledge on the reasons leading to these treatment
changes is scarce. The aim of this study was to identify clinical events preceding anticoagulant switching and NOAC
discontinuation during oral anticoagulant therapy in patients with atrial fibrillation.
Methods
and results
We performed a nationwide register-based study including Danish atrial fibrillation patients initiating a NOAC between
August 2011 and February 2016 (n ¼ 50 623). We explored potential reasons leading to changes in anticoagulant treat-
ment by identifying clinical events preceding switches from vitamin K antagonists (VKA) to NOAC, switches from
NOAC to VKA, and discontinuations of NOACs. Among 23 531 anticoagulant users changing treatment, we identified
13 295 switches from VKA to NOAC, 5206 switches from NOAC to VKA, and 8995 discontinuations of NOACs.
Approximately half of all treatment changes were preceded by a hospitalization. A relevant specific clinical event or
procedure was identified prior to 18.3% of switches from VKA to NOAC, prior to 23.0% of switches from NOAC
to VKA, and prior to 26.6% of discontinuations. Switches from VKA to NOAC were most often preceded by thrombo-
embolic events (7.0%), whereas cardioversion was the most common specific event prior to a switch from NOAC to
VKA (11.4%). Discontinuations were most often preceded by bleeding events (7.6%).
Conclusion For about one in five patients, treatment changes during anticoagulant therapy were preceded by a major clinical event.
However, the majority of patients changed treatment for reasons not recorded in health registries.
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Introduction
Oral anticoagulants effectively prevent ischaemic stroke in patients
with atrial fibrillation (AF) but confer a risk of serious bleedings. In
recent years, a new generation of oral anticoagulants has been intro-
duced: the non-vitamin K antagonist oral anticoagulants (NOACs).
Treatment with NOACs in AF is recommended by international
guidelines and is well-established in clinical practice.1 Accordingly,
a large proportion of newly diagnosed AF patients initiate treatment
with a NOAC.2,3 However, important clinical aspects of NOAC
treatment remain unclarified, thus potentially preventing the opti-
mal use of NOACs.
Drug utilization studies addressing ‘real-world’ NOAC use have
revealed that at least one in three new users of NOACs is switching
from vitamin K antagonists (VKA)3 – 5 and that one in five patients
discontinues NOAC treatment within the first year.3,4,6 Switching
from NOAC to VKA is also observed, although the reported fre-
quency varies considerably.3,5,7,8 While switching or discontinuation
* Corresponding author. Tel: +45 65509443. E-mail address: mmhellfritzsch@health.sdu.dk
The work was carried out at Department of Public Health, University of Southern Denmark, Odense, Denmark.
& The Author 2016. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/),
which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact
journals.permissions@oup.com
Europace
doi:10.1093/europace/euw241
 Europace Advance Access published October 17, 2016
by guest on Novem
ber 29, 2016
D
ow
nloaded from
 
may be based on a rational decision, knowledge about reasons for
these treatment changes during NOAC therapy is essential to evalu-
ate if the observed utilization patterns should cause concern.
The aim of the present study was to investigate clinical events pre-
ceding switches to and from NOAC as well as discontinuation of
NOAC among patients with AF.
Methods
In this nationwide register-based study, we collected health registry data
on all patients with AF who either switched between VKA and NOAC
or discontinued NOAC therapy between August 2011 and February
2016. Using data on hospital contacts, we analysed clinical events pre-
ceding these treatment changes.
Setting and data sources
Virtually all healthcare services in Denmark are furnished by the national
health authorities, thus enabling true population-based studies including
all Danish citizens (5.7 million individuals).9 Data from different Danish
healthcare registries can be linked using the unique personal identifica-
tion number (‘CPR number’) assigned to all citizens.9 In this study, we
obtained data from three nationwide registers. From the Danish Nation-
al Prescription Registry,10 we collected information on filled prescrip-
tions. Patients’ admission history were retrieved from the Danish
National Registry of Patients.11 Finally, we used the Civil Registration
System9 to keep track of study individuals with respect to deaths and mi-
grations. Definitions of drugs, diseases, and procedures used in this
study are detailed in Supplementary material online, Appendix S1.
Study population
The study population consisted of Danish patients initiating a NOAC
(dabigatran etexilate, rivaroxaban, or apixaban) for AF for the first
time in the period of August 2011 to February 2016. To ensure the val-
idity of the AF diagnosis, we required that patients were registered with
a diagnosis of AF in the Patient Registry and were not registered with a
diagnosis of other indications for NOAC (i.e. any history of venous
thromboembolic disease as well as recent hip or knee replacement pro-
cedures). Lastly, to be included, each patient had to have been residing in
Denmark for a minimum of 5 years and had to be ≥18 years old at the
time of filling the first NOAC prescription. A flow chart of the selection
process is provided in Supplementary material online, Figure S1.
Treatment changes
Within the study population, we identified subjects with at least one
treatment change, defined as (i) a switch from VKA to NOAC (defined
as at least one VKA prescription filled within 180 days prior to NOAC
initiation), (ii) a switch from NOAC to VKA (defined as a filled prescrip-
tion for VKA during NOAC treatment, as sustained concomitant treat-
ment with VKA and NOAC is strictly contraindicated12), or (iii) a
discontinuation of NOAC treatment (defined as not filling a prescrip-
tion for any oral anticoagulant in the number of days supplied by the
last NOAC prescription plus 90 days).
Clinical events preceding a treatment
change
As potential reasons for treatment changes, we included hospital diag-
noses compatible with (i) serious clinical events where physicians might
reconsider the indication for anticoagulant treatment (e.g. thrombo-
embolic or bleeding complications), (ii) the emergence of a contraindi-
cation for the given treatment (e.g. mechanical heart valve replacement
during NOAC treatment),12 and finally (iii) indicators of stable sinus
rhythm. Specific events were (i) any hospitalization and hospitalizations
with AF; (ii) a new diagnosis of a thromboembolic event (arterial embol-
ism, venous thromboembolism, ischaemic stroke/transient ischaemic at-
tack, and myocardial infarction); (iii) a new diagnosis of anaemia or
bleeding categorized into (a) any, (b) gastrointestinal, (c) intracranial,
and (d) other bleedings; (iv) a new diagnosis of a contraindication for
VKA and/or NOAC other than bleeding (acute and chronic renal failure,
cancer, and artificial heart valve replacement); and (v) cardioversions
and catheter ablations as indicators of stable sinus rhythm. A diagnosis
was considered ‘new’ when it occurred for the first time within a time
frame of 6 months for acute conditions (thromboembolic complica-
tions, bleeding, and acute renal failure) and 5 years for chronic condi-
tions (cancer, chronic renal failure, and heart valve replacement). Each
individual could contribute with multiple diagnoses.
Finally, to explore if patients had been hospitalized for conditions
other than the ones specified above, we identified the five most fre-
quent unique discharge diagnoses (excluding AF) for hospitalizations
preceding a treatment change.
Analysis
We determined the proportion of patients experiencing hospitalization
as well as each of the pre-specified clinical events prior to the treatment
change. For patients switching from VKA to NOAC or from NOAC to
VKA, we included hospitalizations and events occurring within 60 days
prior to the date of the switch, defined as the date where the prescrip-
tion for the ‘new’ treatment was filled. For patients discontinuing
NOAC treatment, hospitalizations and events were included if they oc-
curred within 180 days prior to the date of discontinuation, defined as
the date following the number of days supplied by the last NOAC pre-
scription plus an additional 90 days.
Analyses were performed using STATA Release 14.1 (StataCorp,
College Station, TX, USA).
Ethics
The study was approved by the Danish Health Data Authority. Accord-
ing to Danish law, no ethical approval was necessary for this study.
What’s new?
† One in five treatment changes involving non-vitamin K antag-
onist oral anticoagulant (NOAC) therapy among patients
with atrial fibrillation was preceded by a major clinical event.
† The most common major clinical event occurring in the per-
iod leading up to a switch from vitamin K antagonist (VKA) to
NOAC was thromboembolism (7.0% of patients).
† The most common major clinical event occurring in the per-
iod leading up to a switch from NOAC to VKA was cardio-
version (11.4% of patients). Among these, 48.9% had an
atrial fibrillation ablation performed subsequently.
† Bleeding was the most common preceding major clinical
event among patients discontinuing NOAC therapy (7.6%
of patients).
† Detailed knowledge on reasons for changes during oral anti-
coagulant therapy requires data collected directly from the
patient or physician.
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Results
Among 50 623 NOAC users with AF, 23 531 (46.5%) experienced
one or more treatment changes during the study period: 13 295 in-
dividuals switched from VKA to NOAC, 5206 switched from
NOAC to VKA, and 8995 discontinued NOAC therapy (Supple-
mentary material online, Table S1). In the latter two groups, 1894
(36.4%) and 2071 (23.0%) had used VKA prior to NOAC initiation,
i.e. had previously switched from VKA to NOAC.
Approximately half of subjects in all three groups were hospita-
lized prior to a treatment change (Tables 1 and 2). Two-thirds of
hospitalizations were coded with a discharge diagnosis compatible
with ‘atrial fibrillation’ and/or one of the predefined clinical events
or procedures. Overall, a predefined clinical event or procedure
was identified prior to 18.3% of switches from VKA to NOAC, prior
to 23.0% of switches from NOAC to VKA, and prior to 26.6% of
NOAC discontinuations.
The frequency of thromboembolic complications was similar in
the three groups (5.6–7.0%). Ischaemic stroke/transient ischaemic
attacks were the dominating events in all three groups and consti-
tuted 64.8% of all thromboembolic events. The emergence of a
new contraindication was most frequent prior to NOAC discon-
tinuation (4.4%), most often cancer (2.8%) and chronic renal failure
(1.0%). Among switchers, bleedings (2.8–4.3%) were less common
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Events potentially contributing to switching
anticoagulant treatment in atrial fibrillation patients in
the period of August 2011 to February 2016
Event VKA to NOACa
(n 5 13 295)
NOAC to
VKAb
(n 5 5206)
Hospitalization
Any hospitalization 40.6% (n ¼ 5402) 45.1% (n ¼ 2348)
Hospitalization with atrial
fibrillation
11.7% (n ¼ 1552) 25.9% (n ¼ 1348)
Hospitalization with a
pre-specified event or
procedure
18.3% (n ¼ 2431) 23.0% (n ¼ 1197)
Hospitalization, otherc 16.3% (n ¼ 2164) 10.4% (n ¼ 544)
Thromboembolic complications
Arterial embolism 0.2% (n ¼ 23) 0.1% (n ¼ 6)
Venous thromboembolism 0.8% (n ¼ 100) 1.2% (n ¼ 61)
Ischaemic stroke/TIA 5.0% (n ¼ 666) 2.7% (n ¼ 142)
Myocardial infarction 1.0% (n ¼ 133) 1.7% (n ¼ 86)
Bleeding complications
Anaemia 2.2% (n ¼ 287) 1.9% (n ¼ 101)
Bleeding, any 4.3% (n ¼ 576) 2.8% (n ¼ 145)
Bleeding, gastrointestinal 1.7% (n ¼ 228) 1.4% (n ¼ 72)
Bleeding, intracranial 0.7% (n ¼ 93) n , 5d
Bleeding, other 2.3% (n ¼ 303) 1.5% (n ¼ 80)
Absolute or relative contraindicationsd
Acute renal failure n/ae 0.5% (n ¼ 26)
Chronic renal failure n/ae 1.2% (n ¼ 61)
Cancer 0.8% (n ¼ 110) 0.6% (n ¼ 31)
Mechanic heart valve
replacement
n/ae 0.2% (n ¼ 12)
Procedures
Direct-current
cardioversion
3.1% (n ¼ 417) 11.4% (n ¼ 595)
Radiofrequency ablation 0.2% (n ¼ 28) 0.3% (n ¼ 16)
Assessed 60 days prior to a switch. Percentage of all patients switching treatment.
VKA, vitamin K antagonist; NOAC, non-vitamin K oral anticoagulant; TIA, transient
ischaemic attack.
aDefined as the first filling of a NOAC prescription among subjects with previous
VKA use.
bDefined as filling a VKA prescription during NOAC therapy.
cDefined as hospitalization with other conditions than atrial fibrillation and
pre-specified events/procedures.
dTo ensure anonymization, cells with numbers lower than five are not reported.
en/a: not a contraindication to the initial drug.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Events potentially contributing to
discontinuation of NOAC treatment in atrial fibrillation
patients in the period of August 2011 to February 2016
Event Discontinuationsa
(n5 8995)
Hospitalization
Any hospitalization 47.4% (n ¼ 4262)
Hospitalization with atrial fibrillation 18.2% (n ¼ 1634)
Hospitalization with a pre-specified event or
procedure
26.6% (n ¼ 2392)
Hospitalization, otherb 14.1% (n ¼ 1264)
Thromboembolic complications
Arterial embolism 0.2% (n ¼ 14)
Venous thromboembolism 0.8% (n ¼ 76)
Ischaemic stroke/TIA 3.4% (n ¼ 306)
Myocardial infarction 1.2% (n ¼ 107)
Bleeding complications
Anaemia 5.6% (n ¼ 500)
Bleeding, any 7.6% (n ¼ 685)
Bleeding, gastrointestinal 3.4% (n ¼ 305)
Bleeding, intracranial 0.9% (n ¼ 80)
Bleeding, other 4.0% (n ¼ 357)
Absolute or relative contraindications
Acute renal failure 0.6% (n ¼ 50)
Chronic renal failure 1.0% (n ¼ 94)
Cancer 2.8% (n ¼ 253)
Mechanic heart valve replacement n, 5c
Procedures
Direct-current cardioversion 6.0% (n ¼ 542)
Radiofrequency ablation 0.3% (n ¼ 25)
Assessed 180 days prior to a discontinuation. Percentage of all patients
discontinuing NOAC treatment.
VKA, vitamin K antagonist; NOAC, non-vitamin K antagonist oral anticoagulant;
TIA, transient ischaemic attack.
aDefined as no filled prescription of any oral anticoagulant in the number of days
supplied by the last NOAC prescription plus 90 days.
bDefined as hospitalization with other conditions than atrial fibrillation and
pre-specified events/procedures.
cTo ensure anonymization, cells with numbers lower than five are not reported.
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than thromboembolic complications (5.7–7.0%). Conversely,
bleedings were more frequent events (7.6%) compared with
thromboembolic events (5.6%) in subjects who discontinued
NOAC treatment. Gastrointestinal bleeding was a more common
type of bleeding among patients using NOACs prior to a switch
or discontinuation than among patients using VKA (45.4 vs. 39.6%
of all bleedings). Intracranial bleedings constituted 16.1 and 11.7%
of bleedings prior to a switch from VKA to NOAC and discontinu-
ation, respectively, and were rare prior to a switch from NOAC to
VKA (,5% of bleeding episodes). Cardioversion had been per-
formed most frequently prior to a switch from NOAC to VKA
(11.4%). The corresponding number was 3.1 and 6.0% for switchers
from VKA to NOAC and patients discontinuing NOAC therapy, re-
spectively. The explorative analysis identifying causes of hospitaliza-
tion outside the pre-specified diagnoses did not contribute with any
new diagnoses (data not shown).
To further explore the mechanisms underlying the observed
treatment changes in relation to cardioversion, we performed
two post hoc analyses. First, receiving numerous cardioversions
may lead to referral for catheter ablation, which in some patients
will involve a switch of anticoagulant treatment (only VKA are cur-
rently recommended for this indication1). We explored this by de-
termining the proportion of patients with a cardioversion prior to a
treatment change that also received catheter ablation within 180
days after the change. This proportion was markedly higher among
patients who had switched from NOAC to VKA upon cardioversion
(48.9%) than among patients who had switched from VKA to
NOAC (4.3%) or discontinued NOAC therapy (1.9%). Second, in
AF patients with a low stroke risk (CHA2DS2-VASc score ¼ 0),
stroke prophylactic treatment with oral anticoagulants is indicated
only in relation to high-risk procedures such as cardioversion.1,12
To explore to which extent temporary NOAC use among low-risk
AF patients could explain the observed discontinuations following
cardioversion, we tabulated CHA2DS2-VASc scores of the 542 pa-
tients discontinuing NOAC therapy after cardioversion. The calcu-
lation of the CHA2DS2-VASc scores is described in Supplementary
material online, Appendix S2. In this specific group, 46% had a CHA2-
DS2-VASc score of 0, 20% had a CHA2DS2-VASc score of 1, and
34% had a CHA2DS2-VASc score of ≥2.
Discussion
In this large nationwide study, including the largest sample to date of
AF patients experiencing treatment changes before and during
NOAC therapy, we found that treatment changes during oral anti-
coagulant therapy in AF is common, with a major clinical event iden-
tified for about one in five patients changing treatment, most often
thromboembolism, bleeding, or cardioversion.
Compared with the present study, prior studies5,13 –17 have gen-
erally identified reasons for treatment changes in a larger propor-
tion of the patients experiencing a change in anticoagulant
treatment. However, these studies are based on data collected dir-
ectly from the patient, physician, or the patient files. Thereby, in add-
ition to major events included in the present study, they include
minor events handled outside the hospital setting. In these studies,
the majority of treatment changes are prompted by minor events
that will rarely lead to hospitalization, e.g. dyspepsia,5,13 – 16 minor
bleedings,5,13 – 17 and change/instability in laboratory values [e.g.
international normalized ratio (INR) and creatinine clear-
ance],5,14– 17 or due to physicians’ or patients’ preference towards
a specific treatment regime.5,14,16 In the Dresden NOAC Registry,5
only 4.5% of 223 treatment changes observed during rivaroxaban
therapy were caused by a thromboembolic event (stroke, transient
ischaemic attack, or acute coronary syndrome). We therefore find
that our study is in line with the previous studies in that only around
one in five treatment changes is preceded by a major clinical event
requiring hospitalization. This is further supported by a previous Da-
nish study reporting that two-thirds of switches to and from NOAC
were carried out by general practitioners.8
Our study expands current knowledge due to its size and, con-
trary to the majority of prior studies, has differentiated between
the types of treatment changes (i.e. switching from VKA to
NOAC, switching from NOAC to VKA, or complete discontinu-
ation). As an example, reasons for switching from NOAC to VKA
specifically have, to the best of our knowledge, been reported
only for 14 AF patients switching from dabigatran to VKA in a study
by Beyer-Westendorf et al.16
Similar to other studies,5,13 – 17 bleedings were among the most
common clinical events preceding a treatment change in the present
study. Bleeding was, however, a less common event prior to a switch
from NOAC to VKA than prior to a switch from VKA to NOAC and
discontinuation. This is in accordance with results from the Dresden
NOAC Registry5,16,17: none of the 14 registered switches from da-
bigatran to VKA were caused by bleeding,16 as opposed to 18% of
568 switches from VKA to NOAC17 and 22% of 32 dabigatran dis-
continuations without subsequent anticoagulant treatment.16 There
is currently no firm evidence addressing whether an AF patient ex-
periencing bleeding during oral anticoagulant therapy (VKA or
NOAC) should continue the treatment, switch to another oral anti-
coagulant, or discontinue oral anticoagulant treatment permanently.
However, a subgroup analysis of the AVERROES trial demonstrated
that AF patients who had previously failed VKA therapy, e.g. due to
bleeding events, profited more from treatment with apixaban than
aspirin in terms of thromboembolic risk and had similar risk of new
bleeding events.18 Furthermore, two recent Danish cohort studies
have explored the risks conferred by re-initiation of anticoagulant
therapy in AF patients experiencing an intracranial19 or gastrointes-
tinal bleeding20 during oral anticoagulant therapy. Compared with
no anticoagulant treatment, both studies found re-initiation to be as-
sociated with lower rates of all-cause mortality and thromboembol-
ic complications while not causing a significantly higher risk of
recurrent bleedings.19,20
In the present study, hospitalizations with AF were more com-
mon prior to switches from NOAC to VKA than prior to the other
types of treatment changes. We believe this to be a reflection of the
high number of cardioversions in this group as an admission with
cardioversion will often be registered with a discharge diagnosis
of AF. Our finding of a high proportion of cardioversions prior to
a switch from NOAC to VKA followed by an AF ablation in almost
half of the patients most likely reflects two distinct clinical issues.
First, as 3–4 weeks of effective and stable anticoagulant treatment
is required prior to cardioversion,1 NOAC may often be preferred
as pre-treatment over VKA in anticoagulant-naive patients. Patients,
who prefer long-term treatment with VKA, may then be switched
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from NOAC to VKA after cardioversion. Second, there is limited
data on the use of NOAC in the context of AF ablation, and, there-
fore, NOAC users should be switched to VKA prior to ablation.1
Our observation that 6% of discontinuations were preceded by a
cardioversion is in accordance with a study by Suzuki et al.15 that
identified a cardioversion prior to 7.6% of 170 discontinuations of
dabigatran. However, in that study, all discontinuations following
cardioversion were scheduled prior to the cardioversion. Thus, all
the involved patients likely had a low stroke risk (i.e. CHA2DS2-
VASc score ¼ 0), and as such anticoagulant therapy was therefore
indicated only due to the high-risk procedure of cardioversion. In
our study, temporary NOAC use among low-risk AF patients in re-
lation to cardioversions could explain only around half of the dis-
continuations that followed a cardioversion.
The principal strength of our study was the nationwide analyses,
including complete follow-up of all Danish citizens registered with
AF and initiating NOAC treatment since the first NOAC was mar-
keted for AF in 2011. Another important strength is the complete-
ness of the registries employed9 – 11 and the high validity of the AF
diagnosis.11 There are limitations as well. Although the majority of
diagnoses used to identify clinical events in the study have been va-
lidated with acceptable results,11 the validity of some diagnoses re-
mains unknown. Furthermore, our data sources did not enable the
identification of patients with poor INR control during VKA therapy,
which was the most common reason for switching from VKA to
NOAC in the Dresden NOAC Registry.17
Conclusion
In conclusion, treatment changes before and during treatment with
NOACs in AF patients are common and about one in five is pre-
ceded by a relevant major clinical event. More research exploring
reasons for specific types of treatment changes related to NOAC
therapy is needed and should preferably be based on data collected
directly from the patient or physician.
Supplementary material
Supplementary material is available at Europace online.
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